Neuroplasticity in the amygdala, a brain center for emotions, leads to increased neuronal activity and output that can generate emotional-affective behaviors and modulate nocifensive responses. Mechanisms of increased activity in the amygdala output region (central nucleus, CeA) include increased reactive oxygen species, and so we explored beneficial effects of monomethyl fumarate (MMF), which can have neuroprotective effects through the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) antioxidant response pathway. Systemic (intraperitoneal) MMF dose-dependently inhibited vocalizations and mechanosensitivity (hindlimb withdrawal reflexes) of rats in an arthritis pain model (kaolin-carrageenan-induced monoarthritis in the knee). Stereotaxic administration of MMF into the CeA by microdialysis also inhibited vocalizations but had a limited effect on mechanosensitivity, suggesting a differential contribution to emotional-affective vs sensory pain aspects. Extracellular single-unit recordings of CeA neurons in anesthetized rats showed that stereotaxic administration of MMF into the CeA by microdialysis inhibited background activity and responses of CeA neurons to knee joint stimulation in the arthritis pain model. Monomethyl fumarate had no effect on behaviors and neuronal activity under normal conditions. The results suggest that MMF can inhibit emotional-affective responses in an arthritis pain model through an action that involves the amygdala (CeA).
Introduction
Evidence suggests neuroprotective effects of fumarate-containing compounds in oxidative stress in central nervous system cells, possibly by stimulating the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway. 4, 17, 49 While dimethyl fumarate (DMF) has been used clinically to treat relapsing forms of multiple sclerosis and psoriasis, 10, 37 the beneficial cytoprotective and antioxidant effects of DMF and its primary metabolite monomethyl fumarate (MMF) in pain management remain to be determined. Despite the fact that DMF is rapidly hydrolyzed to MMF in the body, the 2 fumarates seem to have distinct pharmacological properties and biological activities but both activate Nrf2 to increase antioxidant and cytoprotective gene expression, 17 resulting, for example, in increased levels of the antioxidant glutathione. 1, 23 Reactive oxygen species (ROS), such as superoxide and hydrogen peroxide, play important roles in cytotoxicity and oxidative stress 6, 41, 50 and are also involved in pain pathophysiology. 8, 48 Reactive oxygen species contribute to peripheral 28, 55, 60 and spinal 15, 22, 29, 30, 33, 34, 52, 54, 61 mechanisms of inflammatory and neuropathic pain. Relatively little is known about their role in brain mechanisms of pain, but recent studies have linked ROS in the rostral ventromedial medulla 39 and amygdala 25, 36, 40 to pain facilitation in different pain models.
The amygdala plays a key role in emotional-affective aspects of pain. 43 Neuroplastic changes have been shown to increase amygdala output and behavioral responses in different pain models. The central nucleus (CeA) serves major amygdala output functions and receives nociceptive information through the spinoparabrachio-amygdaloid pathway and highly processed affectrelated information from the lateral-basolateral (LA-BLA) network. 43 CeA activity correlates positively with emotional-affective behaviors and can also modulate pain sensitivity. Therefore, interventions that control CeA activity may be useful therapeutic strategies. Our previous studies showed that inhibition of ROS production inhibits CeA neuronal excitability and responsiveness 25, 36 and supraspinally organized vocalizations, anxiety-like behavior, and spontaneous behaviors, but not spinal reflexes. 25, 40 Therefore, this study tested the hypothesis that MMF can inhibit pain behaviors through an action in the amygdala (CeA) using a rat model of arthritis pain (kaolin-carrageenan-induced monoarthritis in the knee).
Materials and methods
Adult male Sprague-Dawley rats (200-300 g; Envigo, Indianapolis, IN) were housed in a temperature-controlled room and maintained on a 12-hour day/night cycle with unrestricted access to food and water. Experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at Texas Tech University Health Sciences Center (TTUHSC).
Behavioral tests

Experimental protocol
Behavioral tests (see "Pain-related behaviors") were performed before and .5 to 6 hours after arthritis induction (see "Arthritis pain model"). To determine the effects of systemic (intraperitoneal [i.p.]) application of MMF, pain behaviors were measured every 15 minutes for 1 hour postinjection. For effects of MMF in the amygdala, pain behaviors were measured 15 minutes after the onset of stereotaxic administration of MMF by microdialysis (see "Drug application"). Rats were randomly assigned to receive a given intervention. Experimenters were blinded to the treatment (drug or vehicle) but not the pain model. Different investigators performed the tests, and every effort was made to have equivalent testing parameters between rats and treatment groups.
Arthritis pain model
Rats were briefly anesthetized with isoflurane (2%-3%), and monoarthritis was induced by separate injections of kaolin (4% in sterile saline, 100 mL) and carrageenan (2% in sterile saline, 100 mL) into the left knee joint cavity through the patellar ligament followed by repetitive flexions and extensions of the leg for 5 minutes after each injection. This well-established protocol 44 produces an aseptic use-dependent monoarthritis with damage to the cartilage, inflammation of the synovia, and synovial fluid exudate within hours and persists for weeks. Naive animals were used as controls instead of sham-injected animals because of concerns about possible tissue irritation by needle insertion and saline injection into the joint cavity. Our previous studies showed that naive and sham-injected animals are not different .2 hours postinjection and do not develop neuroplasticity and pain behaviors observed in the arthritis model. Vocalizations in the audible (20 to 16 kHz) and ultrasonic (25 6 4 kHz) ranges were measured using a condenser microphone connected to a preamplifier and bat detector connected to a filter and amplifier (UltraVox 4-channel system; Noldus Information Technology, Leesburg, VA), respectively. 44 Rats were briefly anesthetized with isoflurane (2%-3%) and positioned comfortably in a custom-designed recording chamber (U.S. Patent 7,213,538) at a fixed distance from the sound detectors. 20 After habituation to the chamber, brief (15 seconds) innocuous (500 g/30 mm 2 ) and noxious (1500 g/30 mm 2 ) stimuli were applied to the knee with a calibrated forceps equipped with a force transducer, whose output signal was displayed in grams on an liquid crystal display screen. Vocalizations were recorded for 1 minute starting with the onset of the mechanical stimulus and analyzed using Ultravox 2.0 software (Noldus Information Technology, Wageningen, Netherlands).
Mechanical reflex thresholds
Hindlimb withdrawal thresholds were determined after the vocalization measurements while the rat was lightly restrained in the recording chamber. A calibrated forceps with force transducer was used to compress the left knee joint with continuously increasing intensity until a reflex was evoked. The average value from 2 to 3 trials was used as the withdrawal threshold, which was defined as the force required for a reflex response. 44 
Drug applications
Monomethyl fumarate was purchased from Sigma-Aldrich and dissolved in 0.9% isotonic saline, which served as the vehicle control for systemic (i.p.) drug injection (0.5-10 mg/kg MMF). For drug application by microdialysis, rats were anesthetized with isoflurane (2%-3%), and a guide cannula (CMA-Microdialysis, Solna, Sweden) was implanted stereotaxically (David Kopf Instruments, Los Angeles, CA) into the right CeA using the following coordinates: 2.1 mm caudal to bregma, 4 mm lateral to midline, and 7 mm deep. The cannula was fixed to the skull with dental acrylic (Plastic One, Roanoke, VA). Bacitracin ointment was applied to the exposed tissue to prevent infection. On the day of the experiment (next day), a microdialysis probe (CMAMicrodialysis 11) extending 1 mm beyond the cannula was inserted and connected to an infusion pump (Harvard Apparatus, Holliston, MA) with polyethylene tubing. Monomethyl fumarate or artificial cerebrospinal fluid (ACSF, control; containing in mM: 117 NaCl, 4.7 KCl, 1.2 NaH 2 PO 4 , 2.5 CaCl 2 , 1.2 MgCl 2 , 25 NaHCO 3 , and 11 glucose) was applied for 15 minutes at 5 mL/minute before the behavioral tests to establish tissue equilibrium. Monomethyl fumarate stock solution was diluted in ACSF to the final concentration in the microdialysis probe, which was 100 times higher than the target concentration in the tissue because of the concentration gradient across the dialysis membrane and diffusion in the tissue. This approach has been described in our previous publications (see for example, Refs. 19, 25, 46, 59) . Brains were removed after the experiment and stored in 30% sucrose before they were frozen-sectioned to verify the position of the microdialysis probes.
Concentrations for microdialysis administration were based on the literature that reported target concentrations of MMF in the range of 10 to 30 mM, with 15 mM being the most commonly tested concentration although 5 mM was used occasionally. 1, 3, 49, 58 Because of the concentration gradient across the microdialysis membrane a 100-fold higher concentration is needed inside the probe, 12, 31, 36, 46 and so we used 1 mM. For systemic application, DMF and MMF have been shown to be effective at doses of 15, 25, 30, and 50 mg/kg, whereas 5 mg/kg was not effective consistently. 1, 7, 49, 51, 56 We tested doses of 0.5, 1.0, and 10 mg/kg and found maximum effects with 10 mg/kg (Fig. 1 ).
Systems electrophysiology 2.2.1. Experimental protocol
Extracellular single-unit recordings were made from neurons in the laterocapsular division of the CeA in anesthetized rats as described before. [25] [26] [27] Recordings were made in normal animals and in animals with arthritis (.5-6 hours after induction; see "Behavioral tests, Arthritis pain model"). Monomethyl fumarate was administered stereotaxically into the amygdala (see "Drug application"), and neuronal activity was measured every 5 minutes. were measured in normal rats 1 hour after application of MMF (10 mg/kg, i.p.; n 5 7 rats) or vehicle (n 5 7 rats). ns, P . 0.05, unpaired t test. In 2 separate groups of rats, audible (B and C) and ultrasonic (E and F) vocalizations were measured before ("Normal") and 5 to 6 hours after induction of arthritis, and 1 hour after application of vehicle (n 5 8 rats; B and E) or MMF (10 mg/kg, i.p.; n 5 5 rats; C and F). ns, P . 0.05, *,**P , 0.05, 0.01, repeated measures 1-way ANOVA with Bonferroni posttests (see Results for details). Bar histograms show mean 6 SEM. ANOVA, analysis of variance; i.p., intraperitoneal; MMF, monomethyl fumarate.
Animal preparation and anesthesia
Rats were anesthetized with pentobarbital (induction, 50 mg/kg, i.p.; maintenance, 15 mg·kg 21 ·h 21 , i.v.), paralyzed with vecuronium (induction, 0.3-0.5 mg, iv; maintenance, 0.3 mg/hour, iv), and artificially ventilated (3-3.5 mL; 55-65 strokes/min). End-tidal CO 2 levels (kept at 4.0 6 0.2%) and heart rate (using ECG) were continuously monitored. Core body temperature was maintained at 37˚C by means of a homoeothermic blanket system. The animal was mounted in a stereotaxic frame (David Kopf Instr., Tujunga, CA), and a craniotomy was performed at the sutura frontoparietalis level to allow the insertion of the recording electrode and microdialysis probe for drug application.
Single-unit recording and identification of CeA neurons
Individual neurons were recorded with glass-insulated carbon filament electrodes (4-6 MV) using the following coordinates: 2.1 to 2.8 mm caudal to bregma, 3.8 to 4.2 mm lateral to midline, and depth 7 to 8.5 mm. The recorded signals were amplified, bandpass filtered (300 Hz to 3 kHz), processed by an interface (CED 1401 Plus), and displayed on a computer monitor, using Spike2 software (CED, version 4) for spike sorting, data storage, and analysis of single-unit activity. Spike size and configuration were continuously monitored. Only those neurons were included in the study whose spike configuration matched a preset template and could be clearly discriminated from background noise throughout the experiment. A template was created for the spikes of an individual neuron during the initial 5 minutes recording period, capturing the waveform within set limits of variability for parameters such as amplitude, duration, and rise time using Spike 2 software. Subsequent spikes were matched to that template (spike sorting), and only spikes within the set limits of variability were counted as signals of that particular neuron. CeA neurons were identified by monitoring background activity and responses to mechanical compression of the tissue (knee joint) at innocuous (500 g/30 mm 2 ) and noxious (1500 g/30 mm 2 ) intensities with a calibrated forceps. Noxious compression was used sparingly as a search stimulus. One neuron was recorded per animal.
Drug application
For drug application into the amygdala, a microdialysis probe (CMA-Microdialysis 11) was inserted stereotaxically (David Kopf Instruments) into the right CeA while the animal was anesthetized with pentobarbital (see "Animal preparation and anesthesia"). The following coordinates were used: 2.1 mm caudal to bregma, 4 mm lateral to midline, and 7 mm deep. The microdialysis probe was connected to an infusion pump (Harvard Apparatus, Holliston, MA) with polyethylene tubing. Monomethyl fumarate or ACSF (as control) was applied at a rate of 5 mL/minute for 15 to 20 minutes while measurements were made. Monomethyl fumarate stock solution was diluted in ACSF as described in "Behavioral tests, Drug applications." For drug concentrations, see description in "Behavioral tests."
Verification of recording site
At the end of each experiment, the recording site in the CeA was marked by injecting DC (250 mA for 3 minutes) through the carbon filament recording electrode. The brain was removed and submerged in 10% formalin and potassium ferrocyanide. Tissues were stored in 30% sucrose before they were frozen-sectioned at 50 mm. Sections were stained with hematoxylin and eosin (H&E), mounted on gel-coated slides, and coverslipped. The boundaries of the different amygdala nuclei were easily identified under the microscope. Lesion/recording sites and positions of the microdialysis probes were verified.
Statistical analysis
All averaged values are presented as mean 6 SEM. Statistical significance was accepted at the level P
Results
The goal of this study was to test the hypothesis that MMF, which can have Nrf2-mediated antioxidant effects (see Introduction), 2 ) in arthritic rats (5-6 hours after induction). MMF (1 mM, concentration in microdialysis probe; 15 minutes) and ACSF (predrug control) were administered stereotaxically into the central nucleus of the amygdala (CeA, n 5 6 rats) or basolateral amygdala (BLA, n 5 5 rats). ACSF and MMF were tested in the same rats. ns, P . 0.05; **P , 0.01, paired t test. Bar histograms show mean 6 SEM. ACSF, artificial cerebrospinal fluid; MMF, monomethyl fumarate. inhibits arthritis pain-related behaviors through an action in the amygdala output region (CeA). The right amygdala was targeted because of evidence for right-hemispheric lateralization in several pain models. 5, 18, 26, 47 3.1. Effects of systemic and intra-amygdalar monomethyl fumarate on vocalizations
In arthritic rats, 5 to 6 hours after induction of arthritis, systemic (i.p.) MMF inhibited audible and ultrasonic vocalizations to brief (15 seconds) noxious (1500 g/30 mm 2 ) mechanical stimuli (compression of the left knee joint; Fig. 1 ). The effect of MMF (10 mg/kg; n 5 7 rats) was significant compared with vehicle (n 5 1A and B) and was dose-dependent (0.5-10 mg/kg MMF; Fig.  1C ). There was no significant difference between effects of MMF on audible and ultrasonic vocalizations (P . 0.05, F 1,28 5 0.32, 2-way ANOVA), suggesting inhibitory effects on nocifensive and aversive affective responses, respectively.
Based on the time course analysis (Fig. 1) , the 1-hour time point was used to determine the effect of systemic (i.p.) MMF (10 mg/kg), compared with vehicle, on audible (Figs. 2A-C) and ultrasonic (Figs. 2D-F) vocalizations under normal conditions and in the arthritis pain state. In normal rats, systemic (i.p.) MMF (10 mg/kg; n 5 7 rats) had no significant effect on audible ( Fig. 2A) and ultrasonic ( Fig. 2D) vocalizations to brief (15 seconds) noxious (1500 g/30 mm 2 ) stimuli compared with vehicle (n 5 7 rats; P . 0.05, unpaired t test). Vocalizations were measured 1 hour after injection of MMF (10 mg/kg, i.p.) or vehicle. In 2 separate groups of rats, vocalizations were measured before ("normal") and after induction of arthritis, and then vehicle or MMF (10 mg/kg, i.p.) was injected. Vocalizations increased significantly in both the vehicle group (n 5 8 rats; P , 0.01, repeated measures ANOVA with Bonferroni posttest; Figs. 2B and E) and the MMF groups (n 5 5 rats; P , 0.01 and 0.001, audible and ultrasonic vocalizations, respectively; repeated measures ANOVA with Bonferroni posttest; Figs. 2C and F) . Systemic MMF (10 mg/kg, i.p.; n 5 5 rats; Figs. 2C and F), but not vehicle (n 5 8 rats; Figs. 2B and D), inhibited vocalizations of arthritic rats significantly (P , 0.05 and 0.01, audible and ultrasonic vocalizations, respectively; repeated measures ANOVA with Bonferroni posttest).
Stereotaxic administration of MMF (1 mM, concentration in microdialysis probe; 15 minutes) into the central nucleus of the amygdala (CeA, n 5 6 rats), but not basolateral amygdala (BLA, n 5 5 rats), inhibited audible (Fig. 3A) , and ultrasonic (Fig. 3B) vocalizations to brief noxious mechanical stimuli significantly compared with stereotaxic administration of ACSF in the same rats before MMF administration (P , 0.01, paired t tests). Histologically verified sites of drug injection are shown in Figure 4A .
Effects of systemic and intra-amygdalar monomethyl fumarate on mechanical thresholds
In arthritic rats, 5 to 6 hours after induction of arthritis, systemic (i.p.) MMF increased mechanical thresholds for hindlimb withdrawal reflexes evoked by compression of the arthritic knee joint (Fig. 5A) . The effect of MMF (n 5 5 rats) was significant compared with vehicle (n 5 5 rats; P , 0.0001, F 1,48 5 22.65; 2-way ANOVA with Bonferroni posttests). Inhibition of spinal reflexes reached a maximum at 60 minutes after injection of MMF (Fig. 5A) and was dosedependent (Fig. 5B) .
In normal rats, systemic (i.p.) MMF (n 5 5 rats) had no significant effect on mechanical withdrawal thresholds compared with vehicle (n 5 5 rats; P . 0.05, unpaired t test; Fig. 6A ). Thresholds were measured at the left knee joint 1 hour after application of MMF (10 mg/kg, i.p.) or vehicle. In 2 separate groups of rats, mechanical reflex thresholds were measured before and 5 to 6 hours after arthritis induction (Figs. 6B and C) , and then vehicle (6B) or MMF (10 mg/kg, i.p.; 6C) was injected. Thresholds decreased significantly 5 to 6 hours postinduction of arthritis in the vehicle (n 5 5 rats) and MMF groups (n 5 5 rats; P , 0.001, repeated measures ANOVA with Bonferroni posttest). Systemic MMF (10 mg/kg, i.p.; n 5 5 rats; 6C), but not vehicle (n 5 5 rats; 6B), increased thresholds significantly (P , 0.05, repeated measures ANOVA with Bonferroni posttest) 1 hour after drug application.
Stereotaxic administration of MMF (1 mM, concentration in microdialysis probe; 15 minutes) into the CeA (n 5 6 rats), but not BLA (n 5 5 rats), had a small but significant inhibitory effect on withdrawal reflexes (Fig. 6D) , increasing the mechanical threshold at the arthritic knee (P , 0.01, paired t test, compared to ACSF control in the same rats). Figure 4A shows the histologically verified sites of drug injection. The direct comparison of normalized drug effects (% of predrug control; Fig. 6E ) showed that systemically administered MMF (10 mg/kg, i.p.; n 5 5 rats) had a significantly greater effect on mechanical sensitivity than MMF administered into the CeA (1 mM, concentration in microdialysis probe, 15 minutes, n 5 6 rats; P , 0.05, unpaired t test).
Effects of monomethyl fumarate on CeA neurons
The contribution of a direct action of MMF on neuronal activity in the amygdala to its behavioral effects was determined using extracellular single-unit recordings of neurons in the laterocapsular CeA, which has been shown to drive pain-related behaviors. 43 Recordings were made in normal rats and in arthritic rats 5 to 6 hours after arthritis induction. So-called "multireceptive" neurons were selected that responded more strongly to brief noxious than innocuous test stimuli. [25] [26] [27] Mechanical test stimuli were applied to the knee joint using a calibrated forceps as in the behavioral experiments. Artificial cerebrospinal fluid was administered through the microdialysis probe into the CeA before and after MMF. Figure 7 shows the results (A, B, individual examples; C, D, summary).
In normal animals without arthritis, stereotaxic administration of MMF (1 mM, concentration in microdialysis probe; 15 minutes) into the CeA by microdialysis had no effect on background activity of CeA neurons (n 5 7 neurons) and on their responses to innocuous and noxious stimuli (Figs. 7A and C) . In the arthritis pain model (5-6 hours postinduction), MMF significantly inhibited background and evoked activity of CeA neurons (n 5 8 neurons; P , 0.05, paired t test comparing MMF to ACSF in the same neuron; Figs. 7B and D) .
As a control for drug diffusion, MMF (1 mM, concentration in the microdialysis probe) was administered stereotaxically into the adjacent striatum (1.0-1.5 mm away from the laterocapsular CeA) in a different set of experiments. The striatum was selected for offsite controls as in our previous studies 21, 24, 36 because it is close by but does not project directly to the CeA. Monomethyl fumarate administration into the striatum of arthritic rats had no effect on background or evoked activity of CeA neurons (n 5 6; P . 0.05, paired t test comparing MMF with ACSF in the same neuron; Fig. 8 ). Recording sites in the CeA (Fig. 4C) and drug application sites into the CeA and striatum (Fig. 4B) were verified histologically.
Discussion
This study addressed beneficial effects and site of action of MMF in the amygdala in an arthritis pain model. Monomethyl fumarate applied systemically or into the CeA inhibited emotional-affective responses (vocalizations). Systemic MMF also decreased mechanosensitivity (hindlimb withdrawal reflexes), whereas intra-CeA had a much smaller albeit statistically significant effect (Fig. 6E) , which may perhaps suggest a preferential contribution of MMF in the amygdala to emotional-affective aspects of pain. Monomethyl fumarate also inhibited neuronal activity of amygdala neurons when administered into the CeA. The data suggest that MMF can inhibit pain-related changes in the amygdala to affect certain types of pain behaviors while actions outside the amygdala can produce additional effects.
The data were obtained with well-established behavioral and electrophysiological assays. Vocalizations evoked by noxious stimuli reflect supraspinally organized nocifensive (audible vocalizations) and averse-affective (ultrasonic vocalizations) responses. 20, 21 Spinally organized withdrawal reflexes assess mechanosensitivity. These tests have been used successfully before to determine behavioral changes in the arthritis pain model. 44 The arthritis model used here is a monoarthritis in the knee induced by intra-articular injections of kaolin and carrageenan to produce a combination of mechanical damage to the cartilage and localized inflammation. 44 In this model, behavioral changes occur within hours and last for several days. They are causally linked to increased neuronal activity and synaptic plasticity in the CeA based on pharmacological studies showing that decreasing CeA activity inhibit pain behaviors [reviewed in Ref. 43] , whereas increasing CeA output can generate pain behaviors in normal animals. 24, 36 Importantly, mechanisms of pain-related amygdala plasticity include increased ROS, possibly as a consequence of metabotropic glutamate receptor (mGluR5) activation. 36 Accordingly, ROS scavengers in the amygdala can inhibit increased pain behaviors. 25, 36, 40 These findings are consistent with an important role of G-protein-coupled mGluR5 in amygdala plasticity in pain 9, 21, 32, 35, 45 and with an emerging role of ROS in peripheral, 28, 55, 60 spinal, 15, 22, 29, 30, 33, 34, 52, 54, 61 and supraspinal 25, 36, 39, 40, 48 mechanisms of inflammatory and neuropathic pain. Monomethyl fumarate, the primary and bioactive metabolite of DMF, has been shown to be cytoprotective against oxidative challenge through transcription factor Nrf2-dependent antioxidant response element pathway. 4, 16, 17, 49 For example, Nrf2 protects against hydrogen peroxide-induced oxidative injury in the brain through MMF-dependent oxidative stress-induced growth inhibitor 1 (OSGIN1) induction. 4 Monomethyl fumarate and DMF also increase the transcription of genes involved in the synthesis of glutathione, 1,2,23 a major cellular antioxidant against ROS levels.
42 Dimethyl fumarate/MMF-mediated Nrf2 induction has been found in neurons and astrocytes, 38, 49 but this study was not designed to distinguish neuronal and non-neuronal cellular targets.
The mechanisms of MMF effects, which occurred quite rapidly (after 15 minutes) with stereotaxic administration into the amygdala, remain to be determined. Reactive oxygen species Figure 6 . Effects of systemic and stereotaxic MMF on mechanical reflex thresholds in normal and arthritic rats. (A) In normal rats (bar histograms on the left), systemic MMF (10 mg/kg, i.p.; n 5 5 rats) had no significant effect on mechanical withdrawal thresholds compared with vehicle (n 5 5 rats). ns, P . 0.05, unpaired t test. (B and C) Thresholds were also measured before ("Normal") and 5 to 6 hours after induction of arthritis, and 1 hour after application of vehicle (n 5 8 rats; B) or MMF (10 mg/kg, i.p.; n 5 5 rats; C). ns, P . 0.05; *,***P , 0.05, 0.001, repeated measures 1-way ANOVA with Bonferroni posttests (see Results for details). Thresholds were measured at the left knee joint. (D) Stereotaxic administration of MMF (1 mM, concentration in microdialysis probe; 15 minutes) and ACSF (predrug control) into CeA (n 5 6 rats) or BLA (n 5 5 rats). ACSF and MMF were tested in the same rats. ns, P . 0.05; **P , 0.01, paired t test comparing MMF to predrug ACSF in the same rat. Bar histograms show mean 6 SEM. (E) Normalized drug effects (% of predrug ACSF control) of systemically administered MMF (10 mg/kg, i.p.; n 5 5 rats) and intra-CeA administration of MMF (1 mM, concentration in microdialysis probe, 15 minutes, n 5 6 rats). *P , 0.05, unpaired t test. Bar histograms show mean 6 SEM. ACSF, artificial cerebrospinal fluid; ANOVA, analysis of variance; i.p., intraperitoneal; MMF, monomethyl fumarate. scavengers also inhibited neuronal activity and pain behaviors with a similar time course in our previous studies. 25, 36, 40 In addition, glutathione reacts directly with various radical molecules and can interact directly with glutamate receptors to inhibit signaling. 42 By contrast, DMF, but not MMF, inhibits NFkB signaling to reduce proinflammatory cytokines, 17 and so this mechanism seems unlikely to be involved in the effect of MMF. Monomethyl fumarate is also a potent agonist for the cell-surface G-protein-coupled receptor GPR109A, 57 and activation of this receptor blocks inflammation in the colon, 14 ,53 retina, 13 and brain. 11 As such, the antinociceptive effects of MMF might involve multiple pathways that suppress oxidative stress as well as inflammation.
Drug doses and concentrations were selected based on information in the literature (see Methods). Target concentrations of MMF were reported to be in the range of 10 to 30 mM, with 15 mM being tested most commonly although 5 mM was used occasionally. 1, 3, 49, 58 For microdialysis drug application, we used 1 mM because a 100-fold higher concentration is needed inside the probe because of the concentration gradient across the microdialysis membrane as indicated by our own work comparing drug effects in brain slices with microdialysis drug application for a variety of compounds. 12, 31, 36, 46 For systemic application, DMF and MMF have been shown to be effective at doses of 15, 25, 30, and 50 mg/kg, whereas 5 mg/kg was not effective consistently. 1, 7, 49, 51, 56 We tested doses of 0.5, 1.0, and 10 mg/kg and found maximum effects with 10 mg/kg (Fig. 1) .
A number of tests and observations argue against nonspecific actions of MMF. Monomethyl fumarate had no behavioral or electrophysiological effects under normal conditions but only in the pain model, which is consistent with our previous study using a ROS scavenger. 25 Stereotaxic administration into the amygdala (CeA) inhibited vocalizations but not spinal reflexes, which is also consistent with the pattern of effects of a ROS scavenger, NADPH oxidase inhibitor, or lipoxygenase inhibitor in the amygdala. 40 Lack of effects of intra-BLA or striatal injections of MMF also argues in favor of focal effects of CeA injections and strongly suggests that the CeA is indeed the site of action of MMF. It should be noted that the CeA is distinct from BLA in that it receives a dedicated line of nociceptive input from the parabrachial area. 43 The focus of our systems electrophysiology on a well-defined subpopulation of amygdala/CeA neurons that are closely linked to pain modulation 43 may explain the quite consistent effect of MMF.
In conclusion, the results suggest that MMF, the primary metabolite of clinically available DMF, can inhibit pain behaviors through an inhibitory action in the amygdala, an important node for emotional-affective aspects of pain. Mechanisms of actions remain to be determined. The significance of this study extends beyond the field of pain research. Monomethyl fumarate has emerged as a therapeutic target for multiple sclerosis, psoriasis, and other disorders associated with oxidative stress, inflammation, or immune activation. 16 
